Big Profits From A High Flying Penny Stock
The Dynamic Wealth Report
July 24, 2009
Can You Really Triple Your Money In Just One Day?
by Robert Morris, Editor
Do you remember the last time you doubled your money on a stock…
in one day? How about the last time one of them tripled before the
closing bell rang?
Trust me, having a huge one-day winner is absolutely exhilarating. (Not
to mention a huge boost for the ole trading account!)
My Penny Stock Breakouts subscribers can back me up on this point.
Earlier this week, one of my recommendations nearly quadrupled – in just
one day. That’s 278% in less than 24 hours!
As you can imagine, my subscribers are absolutely overjoyed. But, don’t
just take my word for it. Read this excerpt from one of the hundreds of
e-mails we’ve received about the trade:
“I was excited about seeing my email yesterday with a suggestion to sell
half my holdings in a stock you recommended buying. A gain of over 300%
paid for my costs of both subscriptions I had purchased this year.... I
am grateful I purchased my subscriptions to Penny Stock Breakouts and
Penny Speculator…”
So, what was this amazing trade?
-------------Sponsor-------------
Where Can You Turn $300 Into $1.3 Million Right Now?
Our own small-company specialist, Robert Morris, has found a
way to 'sniff out' tiny penny stocks on the verge of a major breakout. And
the timing for this has never been better.
You see, the system takes advantage of an obscure SEC regulation that
sends penny stock prices through the roof.
We've seen some stocks gain 852%... 5,450%... even 17,496% in no time
flat.
Click here
for the details...
-----------------------------------
Here’s a quick recap for you.
In early July, I recommended a short-term trade on biotech stock Human
Genome Sciences (HGSI). I believed we could make a huge profit from an
upcoming event.
You see, HGSI was about to release very important clinical trial results
for their new lupus drug. I knew that if the results were good, the
stock was going to soar. (More on that in a moment.)
First, a little background on lupus.
Lupus is a painful, and sometimes deadly, autoimmune disease. It causes
the body’s immune system to attack its own tissues, blood cells, and
vital organs. Roughly 1.5 million people in the U.S. and 5 million
worldwide suffer from some form of it.
But, HGSI is about to make life for some lupus patients a whole lot
better.
The company’s new drug, BENLYSTA, could become the first FDA approved
treatment for lupus in 50 years. This amazing drug works at the cellular
level to control the disease.
The science behind it is mind-boggling.
And, it’s a potential cash cow. Some estimate BENLYSTA could generate
worldwide sales of $3 billion a year. Now, that’s what I call a
blockbuster drug!
So, getting back to the trade, here’s the key.
With a bit of research, I discovered HGSI was going to report late stage
clinical trial results for BENLYSTA sometime in July. I realized that if
the results were good, the stock would skyrocket.
And, I had a feeling the results would be good.
Here’s why.
In June, HGSI published results from a multi-year continuation trial of
BENLYSTA. The data showed the drug was safe and reduced patients’
symptoms. I couldn’t see how the upcoming data would be any different.
This past Monday, HGSI announced the much awaited results.
Surprise, surprise, they indicated that BENLYSTA is a complete success.
More than half the patients showed significant improvement in their
lupus symptoms. And, the disease isn’t progressing beyond their
originally affected organs.
As you know by now, the stock skyrocketed on the news.
When I recommended it, HGSI was trading at $2.88 a share. On Monday, the
stock jumped to $12.51. That gave us a huge one day return of 334%. And
then on Tuesday, the stock went even higher hitting $14.97. Good
for a whopping 420% gain!
That’s more than five times our money in just two weeks!
So, what’s next for HGSI?
Several upcoming events could send the stock even higher:
- Final Phase III clinical trial results for BENLYSTA in November
(should be just as good as today’s results)
- Application for FDA approval of Albuferon (treatment for Hepatitis C)
this fall
- Application for FDA approval of BENLYSTA in early 2010
- If approved, first Albuferon sales in late 2010
- If approved, first BENLYSTA sales in early 2011
- Further sales of ABthrax (anthrax treatment)
- Two potential blockbuster cancer drugs in mid-stage development
- Two drugs in early-stage development (heart disease and diabetes
treatments)
With all of these potential catalysts happening soon, I think HGSI is
likely to trend higher from here.
I see the stock trading up to at least
the mid to high teens.
Believe it or not, I didn’t write you today to brag about this amazing
trade. Rather, I wanted to give you some insight into some things I look
at before making a recommendation.
Sometimes they work out, sometimes they don’t. But in this particular
case, the end result was nothing short of spectacular.
Congratulations to all of our readers who bagged this winner. And, for
those who didn’t, I invite you to take a close look at my
Penny Stock
Breakouts service.
Click here for details…
• eBay (EBAY) was upgraded to a “Buy” at AmTech
Research, Lazard, and RBC. The analysts note eBay’s latest quarterly
results show improvement in the company’s fundamentals. They also see
signs of recovery in overall e-commerce trends.
• VMware (VMW) was upgraded to a “Buy” at Needham. The
analyst says software vendors should see better overall spending on
software in the second half of the year. He also raised his price target
to $42.
• Citrix Systems (CTXS) was downgraded to a “Hold” at
Needham and Stifel Nicolaus. Both analysts said the move was based on
the stock’s valuation given management’s cautious outlook for the rest
of the year.
Print
Page
Bookmark Us
Home | Whitelist Us |
Terms of Use |
Privacy Policy |
Contact Us | Security |
Site Map